110 related articles for article (PubMed ID: 7719326)
1. Motility- and adhesion factors in bladder carcinoma.
Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H
Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326
[No Abstract] [Full Text] [Related]
2. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
3. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Otto T; Birchmeier W; Schmidt U; Hinke A; Schipper J; Rübben H; Raz A
Cancer Res; 1994 Jun; 54(12):3120-3. PubMed ID: 8205527
[TBL] [Abstract][Full Text] [Related]
4. [Principles of tumor invasion and metastasis].
Otto T; Goepel M; Recker F; Rübben H
Urologe A; 1995 May; 34(3):208-11. PubMed ID: 7610514
[TBL] [Abstract][Full Text] [Related]
5. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M
Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell motility as a novel target in cancer--experimental and clinical results.
Otto T; Luemmen G; Bex A; Suhr J; Goebell PJ; Raz A; Ruebben H
Onkologie; 2002 Apr; 25(2):172-7. PubMed ID: 12006769
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A
Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 expression in relation to apoptosis in primary bladder transitional cell carcinoma.
He LF; Guan KP; Ye HY; Ren L; Yan Z; Wang SW; Hou SK
Chin Med J (Engl); 2005 Dec; 118(24):2093-6. PubMed ID: 16438908
[No Abstract] [Full Text] [Related]
12. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
Crew JP; Fuggle S; Bicknell R; Cranston DW; de Benedetti A; Harris AL
Br J Cancer; 2000 Jan; 82(1):161-6. PubMed ID: 10638984
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
[TBL] [Abstract][Full Text] [Related]
14. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.
Boorjian S; Ugras S; Mongan NP; Gudas LJ; You X; Tickoo SK; Scherr DS
Urology; 2004 Aug; 64(2):383-8. PubMed ID: 15302512
[TBL] [Abstract][Full Text] [Related]
16. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 scores and AgNor counts in transitional cell carcinoma of the bladder: apparent lack of prognostic value.
Zambelli S; Zanin A; Gaglio A; Zai G; Bosco E; Andrion A; Magnani C
Arch Ital Urol Androl; 1993 Dec; 65(6):665-70. PubMed ID: 8312949
[TBL] [Abstract][Full Text] [Related]
18. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
19. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.
Swana HS; Grossman D; Anthony JN; Weiss RM; Altieri DC
N Engl J Med; 1999 Aug; 341(6):452-3. PubMed ID: 10438269
[No Abstract] [Full Text] [Related]
20. [Undifferentiated small-cell carcinoma of the urinary bladder].
Suárez Vilela D; Salas Valien JS; González Morán MA; Giménez Pizarro A
Arch Esp Urol; 1991 Dec; 44(10):1195-8. PubMed ID: 1667892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]